ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 1108 • ACR Convergence 2022

    Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis

    Danielle Stahlbaum1, Renea Jablonski1, Mary Strek2 and Pankti Reid1, 1University of Chicago Medical Center, Chicago, IL, 2University of Chicago, Chicago, IL

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…
  • Abstract Number: 1526 • ACR Convergence 2022

    Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score

    cosimo bruni1, Lorenzo Tofani1, Håvard Fretheim2, Sophie Liem3, Arthiha Velauthapillai4, Hilde Jenssen Bjørkekjær5, Imon Barua2, Ilaria Galetti6, Alexandru Garaiman7, Mike Becker7, Anna-Maria Hoffmann-Vold2, Jeska de Vries-Bouwstra8, Madelon Vonk9, Jörg Distler10, Marco Matucci-Cerinic1 and Oliver Distler7, 1University of Florence, Florence, Italy, 2Oslo University Hospital, Oslo, Norway, 3LUMC, Leiden, Netherlands, 4Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands, 5Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, 6Gruppo Italiano Lotta alla Sclerodermia (GILS), Milano, Italy, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 8Leiden University Medical Center, Leiden, Netherlands, 9Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 10Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: High resolution computed tomography (HRCT) is the gold standard for the diagnosis of systemic sclerosis associated interstitial lung disease (SSc-ILD). Although there is agreement…
  • Abstract Number: 1962 • ACR Convergence 2022

    Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Daniel Kass1, Mehdi Nouraie1, Yingze Zhang1, Bryant England2, Ted Mikuls3, Gail Kerr4, Andreas Reimold5, Kevin Gibson1, Marilyn Glassberg6, Paul Dellaripa7, Tracy Doyle7, Chester Oddis8 and Dana Ascherman8, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5North Texas Veterans Administration Health Care System, Dallas, TX, 6Loyola University Chicago Stritch School of Medicine, Chicago, IL, 7Brigham and Women's Hospital, Boston, MA, 8University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…
  • Abstract Number: 0050 • ACR Convergence 2022

    Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice

    Sung Hae Chang1, Jeongjun Choe2, Seon Uk Kim3, Jeong Yeon Kim4, Sung Won Lee5, Jeong Seok Lee6 and Eun Young Lee4, 1Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, 2Sungkyunkwan University, Seoul, Republic of Korea, 3Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, 4Seoul National University College of Medicine, Seoul, Republic of Korea, 5Sooncheonhyang University College of Medicine, Seoul, Republic of Korea, 6Korea Advanced Institute of Science and Technology, KAIST, Graduate school of Medical Science and Engineering, Daejeon, Republic of Korea

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the pivotal extrapulmonary conditions. However, the pathophysiology of RA-ILD, including the effect of disease-modifying anti-rheumatoid…
  • Abstract Number: 0521 • ACR Convergence 2022

    Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis

    Lauren Smith1, Jamie Perin2, Adrianne Woods2, Fredrick Wigley3, Laura Hummers4 and Ami Shah5, 1Johns Hopkins, District Heights, MD, 2John Hopkins University, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4Johns Hopkins Univerisity, Baltimore, MD, 5Johns Hopkins Rheumatology, Baltimore, MD

    Background/Purpose: Black patients with systemic sclerosis (SSc) develop SSc at a younger age and have more severe disease than White patients, including a higher prevalence…
  • Abstract Number: 1109 • ACR Convergence 2022

    High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease

    Elena Joerns1, David Karp1, Jeffrey Sparks2, Traci Adams1, Una Makris3 and Chad Newton1, 1UT Southwestern, Dallas, TX, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: Interstitial lung disease (ILD) is a disease of lung parenchyma manifesting with inflammation and fibrosis. Interstitial lung disease (ILD) is a frequent complication of…
  • Abstract Number: 1527 • ACR Convergence 2022

    Maintained Complete B Cell Depletion Is Associated with Rituximab Efficacy in Connective Tissue Disorder Interstitial Lung Disease

    Jérôme Avouac1, Roba Ghossan2, Omar Al Tabaa3, Alice Combier2, Alexia Steelandt2, Marion Thomas4 and Yannick Allanore5, 1University of Paris, Paris, France, 2Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, 3Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 4Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 5Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: The benefit of RTX has been suggested for interstitial lung disease (ILD) associated with connective tissue disorders (CTD). Preliminary data have suggested that B…
  • Abstract Number: 2048 • ACR Convergence 2022

    Serology Driven Pulmonary Phenotype Characterization of Sjögren Syndrome-associated Interstitial Lung Disease: A Monocentric Cohort Study

    Gaetano La Rocca1, Francesco Ferro2, Giovanni Fulvio3, Silvia Fonzetti4, Inmaculada Concepción Navarro García5, Elena Elefante6, Chiara Romei7, Marta Mosca6 and Chiara Baldini3, 1University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3University of Pisa, Pisa, Pisa, Italy, 4Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, 5Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 6University of Pisa, Pisa, Italy, 7University of Pisa, Rheumatology Unit, Pisa, Italy

    Background/Purpose: Interstitial lung disease (ILD) is a relatively frequent manifestation of Sjögren's Syndrome (pSS), potentially presenting with a wide spectrum of clinical-radiological characteristics. Anti-Ro52 autoantibodies…
  • Abstract Number: 0123 • ACR Convergence 2022

    Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Disease Associated with Autoimmune Diseases

    Sara Remuzgo-Martinez1, Belén Atienza-Mateo1, Veronica Pulito-Cueto1, Fernanda Genre1, Víctor M. Mora-Cuesta1, David Iturbe-Fernández1, Virgi Portilla1, María Sebastián Mora-Gil1, J Gonzalo Ocejo-Vinyals2, Oreste Gualillo3, Alfonso Corrales1, Santos Castañeda4, Raquel Lopez Mejias5, José M. Cifrián1 and Miguel Ángel González-Gay6, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, 4Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 5IDIVAL, Santander, Spain, 6Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Interstitial lung disease (ILD) may occur in patients with a rheumatic autoimmune disease (AD), increasing their morbidity and mortality [1]. In this regard, the…
  • Abstract Number: 0522 • ACR Convergence 2022

    Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis from EUSTAR

    Anna-Maria Hoffmann-Vold1, Cathrine Brunborg1, Paolo Airò2, Lidia P. Ananyeva3, László Czirják4, Serena Guiducci5, Eric Hachulla6, MENGTAO LI7, Carina Mihai8, Gabriela Riemekasten9, Petros P. Sfikakis10, Gabriele Valentini11, Otylia Kowal-Bielecka12, Yannick Allanore13 and Oliver Distler8, 1Oslo University Hospital, Oslo, Norway, 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, 3V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 4Medical school of Pécs, Pecs, Hungary, 5University of Firenze, Firenze, Italy, 6University of Lille, Lille, France, 7Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 9University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, 10Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, 11Università della Campania “Luigi Vanvitelli”, Napoli, Italy, 12Medical University of Bialystok, Bialystok, Poland, 13Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have been partly successful but have not been tested in a…
  • Abstract Number: 1122 • ACR Convergence 2022

    Short Peripheral Blood Leukocyte Telomere Length in Rheumatoid Arthritis – Interstitial Lung Disease

    Pierre-Antoine Juge1, Tracy Doyle2, Seoyeon Lee3, Avram Walts4, Anthony Esposito5, Sergio Poli de Frias6, Ritu R. Gill7, Hiroto Hatabu8, Mizuki Nishino8, Michael Weinblatt9, Nancy A. Shadick6, Kristen Demoruelle10, Ivan O. Rosas11, Benjamin granger12, Kevin D Deane13, Bruno Crestani14, Paul Wolters15, Philippe Dieude16 and Joyce Lee13, 1Rheumatology department, Bichat Hospital, Paris, France, 2Brigham and Women's Hospital, Boston, MA, 3Department of Medicine, University of California, San Francisco, CA, 4Department of medicine, National Jewish Hospital, Denver, CO, 5Brigham and Women's Hospital, Department of Medicine, Boston, MA, 6Department of Medicine, Brigham and Women's Hospital, Boston, MA, 7Beth Israel Deaconess Medical Center, Radiology Department, Boston, MA, 8Department of Radiology, Brigham and Women's Hospital, Boston, MA, 9Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 10Department of Medicine, University of Colorado, Denver, CO, 11Baylor College of Medicine, Houston, TX, 12Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, 13University of Colorado Denver Anschutz Medical Campus, Denver, CO, 14Hopital Bichat, Paris University, Paris, France, 15UCSF, SF, 16Université Paris Cité, Paris, France

    Background/Purpose: Shortened telomere lengths (TL) have been associated with interstitial lung disease (ILD), in particular idiopathic pulmonary fibrosis (IPF). Given the phenotypic overlap between IPF…
  • Abstract Number: 1528 • ACR Convergence 2022

    Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial

    Janet Pope1, Susanna Proudman2, Wendy Stevens3, Joerg Henes4, Rozeta Simonovska5, Margarida Alves6 and Yannick Allanore7, 1University of Western Ontario, London, ON, Canada, 2Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, 3Department of Rheumatology, St Vincent’s Hospital, Melbourne, Australia, Melbourne, Australia, 4Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 5mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, 6Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 7Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) was developed to quantify organ damage in patients with SSc. We assessed outcomes in the SENSCIS…
  • Abstract Number: 2049 • ACR Convergence 2022

    ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive

    Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Phoung Phoung Diep1, Karoline Lerang2, Birgir Gudbransson1, Helena Andersson1, Øyvind Midtvedt1, Torhild Garen1, Michael Durheim1, Trond Mogens Aaløkken1, Øyvind Palm1 and Øyvind Molberg2, 1Oslo University Hospital, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
  • Abstract Number: 0132 • ACR Convergence 2022

    Pleuroparenchymal Fibroelastosis: A Special Clinical Situation in Patients with Interstitial Lung Disease Associated with Connective Tissue Diseases. Descriptive Study from a Referral Centre

    Belén Atienza-Mateo1, Sara Remuzgo-Martinez1, Diego Ferrer2, Gerardo Blanco Rodríguez3, Sheila Izquierdo Cuervo2, Víctor M. Mora-Cuesta1, David Iturbe-Fernández1, Ricardo Blanco4, José M. Cifrián1 and Miguel Ángel González-Gay5, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Department of Radiology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease (ILD) that can be idiopathic or associated with a variety of different conditions, including connective…
  • Abstract Number: 0585 • ACR Convergence 2022

    Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts

    Takeo Isozaki1, Rei Takahashi2, Kohei Maeda2, Toshihiro Tanioka2, Kunika Shimizu3, Kazutaka Kawamori3, Noriko Konishi4, Shinichiro Nishimi3, Sho Ishii3, Kuninobu Wakabayashi3 and Tsuyoshi Kasama3, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, 3Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Japan, 4Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Baricitinib is a selective small molecule inhibitor of JAK 1…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 39
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology